Profile
Donna M.
Jarlenski formerly worked at Sumitomo Pharma America, Inc., as Director-Clinical Operations & Data Analysis, Vertex Pharmaceuticals, Inc., as Senior Director-Clinical Development Execution, Momenta Pharmaceuticals, Inc., as Senior Director-Development Operations, Purdue Pharma LP, as Director-Clinical Operations, King Pharmaceuticals Research & Development, Inc., as Senior Clinical Research Associate, ClinTrials Research, Inc., as Principal, Pharmaceutical Product Development LLC, as Senior Clinical Research Associate, Tolerx, Inc., as Vice President-Clinical Development & Operations from 2009 to 2011, Mersana Therapeutics, Inc., as Vice President-Clinical Operations from 2015 to 2021, and Aileron Therapeutics, Inc., as VP-Clinical Operations & Project Management.
Ms. Jarlenski received her undergraduate degree from The Pennsylvania State University and graduate degree from Quinnipiac University.
Former positions of Donna M. Jarlenski
| Companies | Position | End |
|---|---|---|
| MERSANA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-04-30 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Chief Operating Officer | 2011-12-18 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
ClinTrials Research, Inc.
 ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The private company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Corporate Officer/Principal | - |
| King Pharmaceuticals Research & Development, Inc. | Corporate Officer/Principal | - |
Training of Donna M. Jarlenski
| The Pennsylvania State University | Undergraduate Degree |
| Quinnipiac University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
| King Pharmaceuticals Research & Development, Inc. | Health Technology |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
ClinTrials Research, Inc.
ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The private company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Commercial Services |
Pharmaceutical Product Development LLC
 Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Purdue Pharma LP
 Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
- Stock Market
- Insiders
- Donna M. Jarlenski
